Introduction: Understanding Glioblastoma and Metabolic Vulnerability
On World Brain Tumor Daywe look at the latest reviews about its use ketogenic metabolic therapy (KMT) for glioblastoma (GBM)the most common malignant primary brain tumor in adults.
This aggressive tumor has a poor prognosis, with a median survival in a sedentary position at approximately 14 months (1, 2). Despite its aggressive nature, glioblastoma presents a distinct metabolic vulnerabilitywhere it is highly dependent on aerobic glycolysis for energy.
The ketogenic diet exploits this vulnerability by:
- Inducing nutritional ketosis.
- Reduction of glycolysis.
- Decreased availability of glucose for cancer cells.
- Allowing healthy cells to easily use ketone bodies for energy (1, 2).
Ketogenic Metabolic Therapy (KMT) as adjunctive therapy
Ketogenic Metabolic Therapy (KMT) has emerged as a promising adjunctive therapy for GBM by targeting glycolysis, reducing insulin and growth signaling, and promoting apoptosis (1, 2). While KMT is primarily described by dietary changes, it also includes physical activity and other lifestyle modifications (1).
Basic information: These interventions render the tumor vulnerable, but alone are not expected to control tumor growth. Instead, they work synergistically with other treatments, including pharmacotherapy, chemotherapy, radiosurgery, and radiation therapy (1-3).
Dietary Goals and the Glucose-Ketone Index (GKI)
Typically, the ketogenic diet used reduces carbohydrates to less than 20 g/day and adjusted to lower blood glucose levels and increase ketones for therapeutic effect (1).
An optimal target occurs when glucose levels are equal to or lower than ketone levels (1). The table below describes the specific treatment zones used in recent research:
| Biomarker | Therapeutic target range |
| Carbohydrate intake | <20g/day (1) |
| Ketone prices | >3.5 mM/L (3, 1) |
| Glucose values | <80 mg/dL (4.4 mmol/L) or 4 mmol/L (3, 1) |
| Glucose-Ketone Index (GKI) | GKI ≤ 2 (1) |
Recent studies on KMT for brain tumors
Recent clinical research continues to support the feasibility of KMT in oncology:
- Research Framework: Duraj et al. (2025) present one of the most comprehensive discussions, including implementation strategies, and present a framework for nutritional and pharmacological KMT research in GBM (1).
- Safety and efficacy: A recent systematic review and meta-analysis comes to this conclusion “Current evidence supports KD as a safe, feasible, and biologically rational adjunct to standard glioblastoma therapy.” Their findings also demonstrate the potential to improve toxicity-free survival and encourage phase III trials to establish clinical guidelines (2).
- Pediatric Applications: Other small studies continue to show promise and are being investigated for pediatric cases with similarly encouraging early results (3-5).
Duraj et al. (2025) present one of the most comprehensive discussions, including implementation strategies, and present a framework for nutritional and pharmacological KMT research in GBM (1). A recent systematic review and meta-analysis concludes that “current evidence supports KD as a safe, feasible, and biologically rational adjunct to the standard treatment of glioblastoma.” Their findings also demonstrate the potential to improve toxicity-free survival and encourage phase III trials to establish clinical guidelines. Other small studies continue to show promise and are being investigated for pediatric cases with similarly encouraging early results (3-5).
Conclusion
More studies are urgently needed to determine the optimal application of KMT in various types of cancer and how best to individualize and optimize therapeutic outcomes.
Professional Resources
THE Food Network offers training, Cancer: metabolic diseasedeveloped in collaboration with Metabolic Terrain Institution of Health (MTHI). This provides participants with:
- Understanding the mechanisms behind cancer as a modern and metabolic disease.
- Information on how to implement TCR (Therapeutic Carbohydrate Restriction) and fasting for cancer treatment.
- The practical tools for understanding, managing and treating cancer patients holistically.
References
- Duraj, T. et al. (2024) “Clinical Research Framework Proposal for Ketogenic Metabolic Therapy in Glioblastoma”, BMC medicine22(1), p. 578. Available at: https://doi.org/10.1186/s12916-024-03775-4.
- Firdous, J. et al. (2026) “Efficacy and safety of the ketogenic diet in glioblastoma: an updated systematic review and meta-analysis”, Neurological Sciences47(5), p. 461. Available at: https://doi.org/10.1007/s10072-026-09035-y.
- Kyryttopoulos, A. et al. (2025) “Successful implementation of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study”, Frontiers in Nutrition11, pp. 1489812. Available at: https://doi.org/10.3389/fnut.2024.1489812.
- Amaral, LJ et al. (2025) “A phase 1 safety and feasibility trial of a ketogenic diet and standard care for patients with newly diagnosed glioblastoma”, Scientific Reports15, pp. 21064. Available at: https://doi.org/10.1038/s41598-025-06675-6.
- AlMutairi, H. et al. (2025a) “Safety, Feasibility, and Efficacy of the Ketogenic Diet in Pediatric Brain Tumor Patients: A Systematic Review.” Journal of Nutrition and Metabolism2025, pp. 7935879. Available at: https://doi.org/10.1155/jnme/7935879.
